Status | Study |
Enrolling by invitation |
Study Name: An Open-Label Extension of a Phase 3 Study of OTX-101 in the Treatment of Keratoconjunctivitis Sicca Condition: Keratoconjunctivitis Sicca Date: 2016-07-24 Interventions: Drug: OTX-101 0.09% 0.09% cyclosporine nanomicellar solution |
Completed |
Study Name: Phase 3 Study of OTX-101 in the Treatment of Keratoconjunctivitis Sicca Condition: Keratoconjunctivitis Sicca Date: 2016-02-13 Interventions: Drug: cyclosporine Other Name: |
Completed |
Study Name: A Safety and Efficacy Study of Tavilermide (MIM-D3) Ophthalmic Solution for the Treatment of Dry Eye Disease Condition: Keratoconjunctivitis Sicca Date: 2016-01-20 Interventions: Drug: 1% Tavilermide Ophthalmic Solution |
Completed |
Study Name: A Safety and Efficacy Study of Tavilermide (MIM-D3) Ophthalmic Solution for the Treatment of Dry Eye Condition: Keratoconjunctivitis Sicca Date: 2015-12-16 Interventions: Drug: 1% Tavilermide Ophthalmic Solution |
Completed |
Study Name: Ocular Surface Dry Eye Microbiome Condition: Dry Eyes Date: 2014-12-01 |
Completed |
Study Name: Phase 2/3 Dose-Ranging Study of the Safety and Efficacy of OTX-101 in the Treatment of Keratoconjunctivitis Sicca Condition: Keratoconjunctivitis Sicca Dry Eye Date: 2014-09-29 Interventions: Drug: OTX-101 0.05% OTX-101 0. |
Completed |
Study Name: A Phase 4 Study Investigating the Efficacy of Retaine™ in Managing Signs and Symptoms Associated With Dry Eye Syndrome Condition: Keratoconjunctivitis Sicca Date: 2014-05-06 Interventions: Drug: Retaine™ |
Completed |
Study Name: A Clinical Study to Assess the Safety and Efficacy of an Ophthalmic Solution (SkQ1) in the Treatment of Dry Eye Syndrome Condition: Keratoconjunctivitis Sicca Date: 2014-04-17 Interventions: Drug: SkQ1 Drug: Placebo SkQ1 (Vehicle) |
Completed |
Study Name: To Assess the Safety and Efficacy of R932348 Ophthalmic Solutions in Patients With Keratoconjunctivitis Sicca Condition: Keratoconjunctivitis Sicca Date: 2013-07-11 Interventions: Drug: R348 Ophthalmic Solution, 0.2% |
Completed |
Study Name: Lotemax® Gel 0.5% and Restasis 0.05% in Subjects With Mild or Moderate Keratoconjunctivitis Sicca Condition: Keratoconjunctivitis Sicca Date: 2013-03-21 Interventions: Drug: Lotemax Gel + Restasis O |